Lupin's Generic Firdapse Approved for Rare Lambert-Eaton Syndrome, but a Patent Deal Delays U.S. Sales to 2035
The FDA approved Lupin's generic Firdapse, but a patent settlement bars U.S. sales until February 2035, limiting near-term savings for patients who need treatment for rare LEMS.
Medical Daily ·